Cancer Therapy News and Research

RSS

Researchers use qHTS approach to examine clinical drugs on thyroid cancer cells

Drugs already approved for clinical use across a variety of therapeutic categories can be screened to identify effective agents for thyroid cancer according to a recent study accepted for publication in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

6 Jan 2012

SonoPhoto Dynamic Therapy shows promise against squamous cell carcinoma

George Miller developed an ulcer on his bottom lip that began to bleed. His doctor sent cell scrapings to a pathologist, and diagnosed Miller with squamous cell carcinoma (SCC). According to TMD Limited, a medical tourism company, squamous cell carcinoma is the 2nd most common cancer in humans and other animals.

6 Jan 2012

New anti-tumor compounds show promise for hard-to-treat cancers

New anti-tumor compounds produced by Dr. Aleem Gangjee, Distinguished Professor of Medicinal Pharmacy at Duquesne University's Mylan School of Pharmacy, show such promise for fighting hard-to-treat tumors that the National Institutes of Health (NIH) has placed them on its fast track for development.

6 Jan 2012

New brochure makes planning and monitoring post-cancer exercise easy

Not only is overall quality of life higher in cancer survivors who exercise, but the rate of cancer recurrence is lower. Unfortunately, though most doctors recommend exercise, many patients fail to follow through.

5 Jan 2012

PEDF may suppress brain from tumor-induced damage, metastasis

Scientists are one step closer to repairing the damage caused by brain metastasis, a major challenge in cancer treatment, according to data published in Cancer Research, a journal of the American Association for Cancer Research.

4 Jan 2012

Antigen Express to move AE37 cancer vaccine into larger clinical trials

Generex Biotechnology Corporation today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37.

4 Jan 2012

iCAD enters $15M debt facility agreement with Deerfield Management

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that it has entered into a five year, $15 million debt facility agreement with Deerfield Management Company LP, a leading healthcare investment fund.

3 Jan 2012

Astellas, AVEO announce results of tivozanib and sorafenib comparison trial on RCC

AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc. today announced that tivozanib demonstrated superiority over sorafenib in the primary endpoint of progression-free survival (PFS) in TIVO-1, a global, randomized Phase 3 clinical trial evaluating the efficacy and safety of investigational drug tivozanib compared to sorafenib in 517 patients with advanced renal cell carcinoma.

3 Jan 2012

New initiative to detect cancers in earliest stages inside cells

A team of cancer imaging experts at Johns Hopkins has embarked on a five-year research initiative to speed development of early diagnostic tests and new treatments for breast, prostate and other common cancers.

29 Dec 2011

Researchers decode and characterize DNA repair mechanism

Oxidative stress is the cause of many serious diseases such as cancer, Alzheimer's, arteriosclerosis and diabetes. It occurs when the body is exposed to excessive amounts of electrically charged, aggressive oxygen compounds. These are normally produced during breathing and other metabolic processes, but also in the case of ongoing stress, exposure to UV light or X-rays. If the oxidative stress is too high, it overwhelms the body's natural defences. The aggressive oxygen compounds destroy genetic material, resulting in what are referred to as harmful 8-oxo-guanine base mutations in the DNA.

28 Dec 2011

UVA outreach librarian receives national award

Whether helping cancer patients find accurate information or caregivers for Alzheimer's patients overcome a sense of isolation, Ann Duesing has spent 16 years connecting Southwest Virginia residents with information to help them live healthier lives.

26 Dec 2011

CEL-SCI reports net loss of $26.8M for fiscal year ended September 30, 2011

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2011.

26 Dec 2011

Oregon hospitals lose battle against new law; Pittsburgh hospital, insurer reach agreement

The Oregon Association of Hospitals and Health Systems lost an attempt to stop the implementation of a new law that will reduce their outpatient reimbursements by up to 50% starting January 1.

23 Dec 2011

Scientists discover mechanism by which TNFα stimulates tumor formation

An inflammation-promoting protein triggers deactivation of a tumor-suppressor that usually blocks cancer formation via the NOTCH signaling pathway, a team of researchers led by scientists at The University of Texas MD Anderson Cancer Center reports today in Molecular Cell.

23 Dec 2011

Researchers identify previously unknown gene fusion event in lung cancer

Smoking is a well-known risk factor for lung cancer, but nearly 25% of all lung cancer patients have never smoked. In a study published online today in Genome Research, researchers have identified a previously unknown gene fusion event that could explain a significant proportion of lung cancer cases in never-smokers, and might serve as a target for new therapies.

23 Dec 2011

Memorial Sloan-Kettering Cancer Center joins The Robertson Foundation

As an enduring tribute to a valued Board member and woman of incomparable grace, Memorial Sloan-Kettering Cancer Center has joined with The Robertson Foundation to undertake two high-profile initiatives in honor of Josephine "Josie" Robertson: the Josie Robertson Surgery Center and the Josie Robertson Investigators Program.

22 Dec 2011

AVEO initiates enrollment in tivozanib and mFOLFOX6 Phase 2 combination trial for CRC

AVEO Pharmaceuticals, Inc. today announced the initiation of patient enrollment in an open-label, multicenter, randomized Phase 2 clinical trial, called BATON-CRC, evaluating tivozanib in combination with modified FOLFOX6 (mFOLFOX6) compared to bevacizumab in combination with mFOLFOX6 as first-line therapy in patients with advanced metastatic colorectal cancer.

22 Dec 2011

Researchers discover how c-MYC facilitates tumor growth

Cancer cells are essentially immortal. The acquisition of an unlimited capacity to divide - the process of immortalization - is a central event in the genesis of tumors. Normally, cells are subject to stringent mechanisms which control their proliferation. Together these ensure that pre-malignant cells are induced to enter a senescent, non-dividing state or to undergo apoptosis, i.e. commit suicide.

22 Dec 2011

EETs may also drive growth and spread of cancer

A group of small molecules called EETs - currently under scrutiny as possible treatment targets for a host of cardiovascular diseases - may also drive the growth and spread of cancer, according to researchers at the Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and other institutions.

20 Dec 2011

Hebrew University student wins Kaye Innovation Award for anti-cancer therapy

A strategy for inhibiting a protein that is associated with the spread of cancer has won for a Hebrew University of Jerusalem Ph.D. student in chemistry one of this year's Kaye Innovation Awards at the university.

20 Dec 2011